MedPath

Investigation for the prevalence of anti-SARS-CoV-2 antibody.

Not Applicable
Conditions
COVID-19
Registration Number
JPRN-UMIN000046246
Lead Sponsor
Fukuoka City Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
281
Inclusion Criteria

Not provided

Exclusion Criteria

None

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The influence of post-vaccination reactions and use of antipyretic medications on the anti-SARS-CoV-2 spike antibody titer
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath